I

Integra LifeSciences

Regenerative medicine, surgical devices provider

Senior Regional Product Marketing Manager

Full-TimeUpdated on 10/23/2026
$125.3k - $172.5k+ Bonus + Commission + Equity
Expert
Bachelor's, Master's, MBA
Irvine, CA, USA+2 moreMore locations: Mansfield, MA, USA | Princeton, NJ, USA
In PersonTravel approximately 25%.
Growth & MarketingProduct Marketing

About the job

Requirements
  • A bachelor's degree or equivalent and 12+ years of total work experience are required.
  • At least 8 years of experience in marketing and/or commercial functions within medical device or healthcare-related fields is required.
  • Excellent conceptual problem-solving skills and the ability to bring structure and process to vaguely defined problems are required.
  • Strong project management, written communication, verbal communication, and presentation skills are required.
  • The candidate must be able to collaborate, lead, operate, and influence cross-functionally, including without authority.
  • Demonstrated problem-solving skills, including the ability to structure an approach and manage execution, are required.
  • The candidate must be able to collect, process, and analyze data and demonstrate capability using Copilot or other AI tools to support data-driven decision-making.
  • The candidate must be able to manage multiple tasks, events, and appointments independently with limited oversight while maintaining production.
  • The candidate must be able to communicate clearly, accurately, concisely, and compellingly to different audiences.
  • The candidate must be able to take initiative, lead without authority, and mentor other team members.
  • The candidate must be able to build effective relationships with internal collaborators, field representatives, and external healthcare professional customers.
  • The candidate must be able to react independently with appropriate speed in support of department priorities and business objectives.
Responsibilities
  • Identify and implement U.S. product strategies, marketing plans, promotional programs, forecasting, and other marketing activities for the Neuro Critical Care and MIS Neurosurgery product lines.
  • Execute commercial activities for assigned products and develop and coordinate product launches and product marketing to support regional revenue and growth targets.
  • Lead development of product marketing plans, including objectives, strategies, tactics, profit-and-loss projections, and short- and long-term strategies.
  • Participate in strategic sales and marketing planning for customer segmentation, targeting, and promotion.
  • Develop and implement product-marketing deliverables, including claims matrices, competitive analyses, launch plans, and promotional assets such as web content, social media, and brochures.
  • Coordinate with Marketing Communications and other departments to position products appropriately.
  • Own downstream New Product Introduction planning and execution, including positioning collateral, social media or digital promotion, field communication, performance metric collection, and forecasting.
  • Work with the Sales Advisory Council to ensure deliverables are high quality and relevant to its needs.
  • Collaborate with professional education and medical affairs to enhance product-marketing activities, including surgeon education programs, white papers, testimonials, and clinical study summaries.
  • Collaborate with field personnel on surgeon and key-account visits, customer relationship management, and customer engagement as needed.
  • Work with Regulatory, Legal, Medical Affairs, and Product Development stakeholders to ensure assets comply with requirements and expedite copy approval before release to internal and external customers.
  • Build revenue forecasts for the Neuro Critical Care and MIS Neurosurgery product lines and update demand forecasts to support accurate supply and operational planning and net revenue targets.
  • Monitor forecasts and collaborate with other departments to maintain product availability throughout the product lifecycle.
  • Maintain regular contact with strategic industry experts, trade organizations, and scientific societies, and participate in key meetings and conferences to position the company and its products favorably against competitors.
  • Support the company’s medical education initiative by assisting with the preparation and delivery of surgeon training courses when needed.
Desired Qualifications
  • A master's degree or MBA is preferred.
  • Operating room or Neuro Intensive Care product technology experience is strongly preferred.

About the company

Integra LifeSciences develops medical technologies for tissue repair and regeneration, including tissue-regeneration scaffolds, neurosurgical devices, wound care products, and specialized surgical instruments. Its scaffolds are implanted on wounds to provide a temporary matrix that guides new tissue growth and gradually integrates with the patient's tissue. The company differentiates itself through a diversified, multi-domain portfolio built via acquisitions, spanning regenerative medicine and conventional medical devices. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Plainsboro Township, New Jersey

Founded

1989

Get referred to Integra LifeSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $391.9 million, with organic growth and raised EPS guidance.
  • S&P upgraded Integra to B on October 1, 2026, citing normalization progress.
  • Management targets $200 million operating cash flow in 2026, aided by cost savings.

What critics are saying

  • Cincinnati flooding cuts Q3 revenue $7 million and Q4 revenue $15 million to $20 million.
  • The Cincinnati plant returns only in Q2 2027, extending customer loss and backlog risk.
  • Boston cGMP securities litigation threatens damages, injunctions, and existential brand erosion.

What makes Integra LifeSciences unique

  • Integra spans neurosurgery, wound care, and reconstructive biologics, reducing single-product dependence.
  • Braintree's June 2026 ramp and Q4 2026 SurgiMend relaunch restore proprietary supply control.
  • 2027 Liberties launch and SurgiMend PMA target create new neurosurgery and breast-reconstruction wedges.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical Insurance
  • Dental Insurance
  • Vision Insurance
  • Short-Term Disability
  • Long-Term Disability
  • 401(k) Retirement Plan

Growth & Insights and Company News

6 month growth

0%

1 year growth

4%

2 year growth

4%
Yahoo Finance
Oct 22nd, 2026
Integra LifeSciences shares fall 11% despite $411.2M Q3 revenue and return to profit

Integra LifeSciences shares fell about 11% in the first full session after its third-quarter 2026 results, as investors focused on refinancing worries and a high price-to-earnings ratio. Revenue rose to $411.2 million from $402.1 million a year earlier. The company posted a net profit of $14.9 million, against a $5.4 million loss, or basic earnings per share of $0.19. Operating cash flow reached $96 million, and net leverage fell to 3.8x. Net debt remains about $1.6 billion. Integra plans to refinance through new $450 million 9.5% notes, at an estimated 100 to 200 basis points higher rate. It also forecasts higher interest costs in 2027 and a softer fourth-quarter organic outlook.

Associated Press
Oct 9th, 2026
Integra prices $450M senior secured notes at 9.5% to refinance credit facilities

Integra LifeSciences Holdings Corporation has priced $450 million in senior secured notes due 2033, carrying a 9.500% interest rate. The medical technology company expects to close the sale on or around 19 October 2026, subject to customary closing conditions. The notes will be general senior secured obligations guaranteed by Integra's wholly-owned domestic subsidiaries that guarantee the company's existing senior secured credit facilities. Integra plans to use proceeds from the offering, combined with borrowings under new credit facilities, to refinance existing credit facilities and cover associated fees and expenses. The offering forms part of a broader refinancing transaction. The notes were offered only to qualified institutional buyers and certain non-US persons, relying on exemptions from Securities Act registration requirements. Integra LifeSciences is a global medical technology company specialising in neurosurgery and tissue reconstruction.

Associated Press
Oct 2nd, 2026
Integra LifeSciences cuts 2026 guidance after Cincinnati flooding disrupts production

Integra LifeSciences has lowered its full-year 2026 financial guidance following flooding at its Cincinnati manufacturing facility in July. The medical technology company now expects annual revenue of $1.634 billion to $1.654 billion, down from previous guidance of $1.654 billion to $1.695 billion. The flooding disrupted production of several products in the company's Specialty Surgical Technologies portfolio. Integra estimates the supply disruption reduced third quarter revenue by approximately $7 million and will impact fourth quarter revenue by $15 million to $20 million. The company expects third quarter revenue of $410 million to $412 million and adjusted earnings per share of $0.55 to $0.59. Full-year adjusted earnings per share guidance has been revised to $2.30 to $2.40, down from $2.40 to $2.50. Integra maintains property and business interruption insurance and expects recoveries to mitigate a substantial portion of the earnings impact. The facility is expected to return to full manufacturing operations during the second quarter of 2027.

MarketScreener
Oct 2nd, 2026
Integra LifeSciences Launches $600 Million Senior Secured Term Loan B

Integra LifeSciences said Friday that it has launched a $600 million seven-year senior secured term loan B as part of a broader refinancing transaction. The medical technology company said it...

Yahoo Finance
May 29th, 2026
Integra LifeSciences shares jump 6% after Citigroup upgrades rating and raises price target to $16

Integra LifeSciences shares rose 6.1% after Citigroup upgraded its rating from Sell to Neutral and raised its price target to $16 from $11. Analyst Joanne Wuensch's upgrade reflects reduced downside risk, though not yet a bullish outlook. The upgrade follows strong first-quarter 2026 results reported 22 days earlier, when the stock gained 5.3%. Integra's revenue grew 2.4% year-on-year to $391.9 million, beating estimates, whilst adjusted earnings per share of $0.54 exceeded consensus by 32.8%. The company raised its full-year earnings guidance and appointed Stuart Essig as CEO. Integra shares are up 36.7% year-to-date and recently hit a 52-week high of $16.42, though five-year returns remain significantly negative.